Chemomab Therapeutics Ltd DRC Cash Flow Conversion Efficiency
Chemomab Therapeutics Ltd DRC cash flow conversion efficiency. Based on the latest financial reports, Chemomab Therapeutics Ltd DRC (CMMB) has a cash flow conversion efficiency ratio of -0.910x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.22 Million) by net assets ($12.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Chemomab Therapeutics Ltd DRC (2015–2025)
Cash flow conversion efficiency of Chemomab Therapeutics Ltd DRC from 2015 to 2025. This chart illustrates how Chemomab Therapeutics Ltd DRC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CMMB live share price for real-time trading data and today's change.
Chemomab Therapeutics Ltd DRC Cash Flow Conversion Ratio Explained
Chemomab Therapeutics Ltd DRC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Chemomab Therapeutics Ltd DRC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chemomab Therapeutics Ltd DRC ranked by their cash flow conversion efficiency. Also see how much is Chemomab Therapeutics Ltd DRC worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Green Earth Group N.V.
AS:HWK
|
0.038x |
|
Erria A/S
CO:ERRIA
|
0.381x |
|
Flexidynamic Holdings Bhd
KLSE:0231
|
0.121x |
|
Suzhou Goldengreen Technologies Ltd
SHE:002808
|
-0.049x |
|
COSCIENS Biopharma Inc.
NASDAQ:CSCI
|
-0.627x |
|
YLI Holdings Bhd
KLSE:7014
|
-0.016x |
|
Swissnet AG
F:81D
|
N/A |
|
CS Corporation
KQ:065770
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Chemomab Therapeutics Ltd DRC (2015–2025)
The table below shows the annual cash flow conversion efficiency of Chemomab Therapeutics Ltd DRC from 2015 to 2025. Review Chemomab Therapeutics Ltd DRC leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $12.33 Million | $-11.22 Million | -0.910x | +20.35% |
| 2024-12-31 | $13.54 Million | $-15.46 Million | -1.142x | +17.58% |
| 2023-12-31 | $17.00 Million | $-23.55 Million | -1.386x | -147.35% |
| 2022-12-31 | $36.22 Million | $-20.29 Million | -0.560x | -178.05% |
| 2021-12-31 | $61.47 Million | $-12.38 Million | -0.201x | +83.00% |
| 2020-12-31 | $10.80 Million | $-12.80 Million | -1.185x | -7.01% |
| 2019-12-31 | $14.91 Million | $-16.51 Million | -1.107x | +23.41% |
| 2018-12-31 | $9.80 Million | $-14.18 Million | -1.446x | -110.26% |
| 2017-12-31 | $-609.00K | $-8.58 Million | 14.090x | +1342.12% |
| 2016-12-31 | $3.29 Million | $-3.74 Million | -1.134x | +67.03% |
| 2015-12-31 | $2.14 Million | $-7.38 Million | -3.441x | -- |
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical tri… Read more